Search
elinzanetant (Lynkuet)
Indications:
- vasomotor symptoms of menopause* (FDA-approved) [4]
- improves sleep disturbances & menopause-related quality of life*
* elinzanetant with greater reduction in vasomotor symptom frequency & severity & improved sleep quality vs fezolinetant [2]
Dosage:
- 120 mg PO QHS*
* Take capsules at bedtime (due to somnolence potential) [1,3]
Adverse effects:
- headache & fatigue most common (7-9% vs 2.5-2.6% for placebo)
- no serious adverse effect in clinical trial [1]
Drug interactions:
- avoid strong inhibitors or inducers of CYP3A4, including grapefruit juice
Mechanism of action:
- selective neurokinin-1,3 receptor antagonist
General
endocrine agent
receptor antagonist
Database Correlations
PUBCHEM correlations
References
- Pinkerton JV, Simon JA, Joffe H et al
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause.
OASIS 1 and 2 Randomized Clinical Trials.
JAMA. Published online August 22, 2024.
PMID: 39172446
https://jamanetwork.com/journals/jama/fullarticle/2822766
- Menegaz de Almeida A, Oliveira P, Lopes L, et al.
Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor
Symptoms: A Systematic Review and Meta-analysis.
Obstet Gynecol. 2025 Jan 2
PMID: 39746208
- Panay N, Joffe H, Maki PM, et al.
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause:
A Phase 3 Randomized Clinical Trial.
JAMA Intern Med. 2025 Sep 8:e254421
PMID: 40920404 PMCID: PMC12418220
- Monaco K
Novel Nonhormonal Drug Approved for Menopause Hot Flashes.
Elinzanetant is the first dual neurokinin targeted therapy for this indication.
MedPage Today October 24, 2025
https://www.medpagetoday.com/obgyn/menopause/118141